Hi [[ session.user.profile.firstName ]]

Life Sciences

  • Using machine learning to identify adverse events from scientific literature
    Using machine learning to identify adverse events from scientific literature
    Umesh Nandal Recorded: Feb 19 2020 61 mins
    Information found in the biomedical literature is a significant source for tracking and reporting adverse drug reactions (ADR). The EMA and FDA have both mandated that market authorization holders maintain active screening of literature for any mentions of ADRs related to their drugs or other medicinal products. Given the increasing amount of literature, manual screening, reviewing and monitoring literature costs more time, money and creates an additional compliance risk. Using the advanced technologies in Artificial intelligence (AI), Machine learning (ML) and Natural language processing (NLP), we have developed models to identify Adverse events (AE) in the literature, which can save considerable time and effort in large-scale analysis and in integrating data from multiple diverse information sources.

    This webinar will discuss:
    - the challenges of literature mining using AI
    - the Biomedical Named Entity Recognition (BNER) and its advantages for information extraction tasks
    - how to create a quality training set for machine learning
    - the experiment outcome and further applications

    About speaker:

    Umesh Nandal, PhD, is the Principal Machine Learning & NLP scientist in Content Transformation (CT) department at Elsevier. With a background in Chemistry and computational biology, Umesh is applying state-of-the-art methods in ML and NLP to improve or build new life science products of Elsevier that can help researchers in getting correct answers to their questions quickly. Prior to joining Elsevier, he used various ML and computational approaches to analyse molecular data generated from high-throughput technologies to understand biological processes in healthy and diseased organisms. During his PhD, he intensively worked on the comparison of mouse models with humans by building a network based integration method that can compare their biological networks.
  • High-Resolution Characterization of Structure, Interaction, and Miscibility
    High-Resolution Characterization of Structure, Interaction, and Miscibility
    Eric Munson, Professor and Head at Purdue University Recorded: Feb 11 2020 60 mins
    Full Title: High-Resolution Characterization of Structure, Interaction, and Miscibility of Drug Products

    The local interactions between a drug and its surrounding environment is critical in both small and large molecule formulations. For small molecules, the drug-polymer interaction is needed to ensure that the drug does not crystallize in an amorphous solid dispersion. For proteins, phase separation in lyophilized formulations will lead to reduced stability and the potential for aggregation. In this presentation, the ability to probe these local structures and interactions in both small and large molecule systems will be shown. Case studies will be presented that demonstrate how structural properties (e.g. degrees of interaction, changes in conformation) can impact functional properties such as crystallization and aggregation.

    Eric Munson of Purdue University

    Eric Munson, Ph.D., is currently Professor and Head of the Department of Industrial and Physical Pharmacy at Purdue University. He received his B.A. degree from Augustana College in Sioux Falls, South Dakota, in 1987. After studying one year in Munich, Germany, on a Fulbright Fellowship, he received his Ph.D. in 1993 from Texas A&M University, and was a postdoctoral fellow at the University of California, Berkeley in 1994. He was in the Chemistry Department at the University of Minnesota before moving in 2001 to the Pharmaceutical Chemistry Department at the University of Kansas, to the Pharmaceutical Sciences Department at the University of Kentucky in 2010, where he was the Patrick DeLuca Endowed Professor in Pharmaceutical Technology. In 2018 he moved to Purdue University to become Professor and Head of the department. His research program is focused on the characterization of pharmaceutical solids using a variety of analytical techniques, with an emphasis on solid-state NMR spectroscopy. Dr. Munson is a coinventor on three patents and has published more than 100 research, review, and book chapters.
  • Applying behavioural interventions in chronic diseases
    Applying behavioural interventions in chronic diseases
    Cara Blair, Robert Poole, Ian Greenway, Pippa Colden, Complete HealthVizion, Dominic Tyer, pharmaphorum Recorded: Feb 6 2020 62 mins
    Chronic diseases are the leading cause of death and disability worldwide and have a staggering impact on patients’ lives and the provision of healthcare around the world.

    Tackling conditions such as diabetes, heart disease and stroke is of vital importance if patient outcomes are to be improved and healthcare costs lowered.

    To achieve this, and in doing so address clinical inertia, a combination of innovative communication strategies and behavioural science can provoke small changes that produce a meaningful difference in health outcomes.

    This pharmaphorum webinar, in association with Complete HealthVizion, will look at how to help chronic disease patients to live well for longer, by providing a clear understanding of healthcare professionals’ and patients’ behaviours and communication needs.

    Focus

    The webinar will take place on Thursday 6th February from 14:00-15:00 GMT/09:00-10:00 EST, when a world-class faculty representing a wide-range of disciplines, including social science, multichannel and medical affairs strategy, will discuss how behavioural change approaches can be used to avoid major health problems and the increasing costs associated with declining health.

    They will consider drivers of decision making in chronic disease management and look at why issues such as ‘behavioural complacency’ prevent progress and consider the lack of short-term benefits associated with many disease management approaches.

    All too often there is little urgency to act in patients at risk from chronic disease, despite a growing burden that increases their suffering and the time they spend in clinical practices with HCPs.

    This webinar will help change that, by looking at:

    •How to assess readiness to change among patients and HCPs
    •What strategic approaches work best in this setting
    •How to target the most important HCPs and convince them of the need for change
    •How to measure the effectiveness of behavioural change tactics
  • Reaxys PhD Prize 2020 - Tips and Tricks for Applicants
    Reaxys PhD Prize 2020 - Tips and Tricks for Applicants
    Dr Friedrich Kroll and Alica May - Reaxys PhD Prize team Recorded: Feb 5 2020 32 mins
    This webinar will provide interested applicants with an overview of the prestigious Reaxys PhD Prize competition. It will cover submission requirements, eligibility criteria, deadlines and walk researchers through the application platform. Be sure to tune in if you are a young chemist and are thinking of applying to the 10th anniversary of this global competition! There will be plenty of time for Q&A at the end.
  • Informed patients: evolving healthcare, clinical trials and medical information
    Informed patients: evolving healthcare, clinical trials and medical information
    Andrew Schorr, Patient Power, Dominic Jack, Merck, Vale Nicoli-Carr, mdgroup, Dr Vidal Pérez, Cardiologist, Dom Tyer, pp Recorded: Feb 5 2020 62 mins
    Overview

    Patients are more informed than ever about their conditions and what is available for them to improve their quality of life.

    The healthcare sector is increasingly focused on understanding patient needs and engaging them in the clinical development and medical information process. Therefore, it is paramount to create patient-focused educational content using a range of communication channels and digital tools.

    However, do we take any time to think like a patient and, by doing so, understand their evolving needs and how this will affect the development of clinical trials and other healthcare educational initiatives?

    This pharmaphorum webinar, held in association with Plenum and mdgroup, takes place on Wednesday 5th February from 14:00-15:00 GMT and will look at the impact of patient involvement, from clinical programme design through to launch and post-launch activities.

    Focus

    • What should patient-led communication look like and who will provide it?
    • How to best meet patients’ needs during clinical trials
    • Which meeting formats and other channels are most relevant to reach the broadest and most appropriate audiences?
    • What role will each stakeholder play in the future?

    Register to find out more and be part of this exciting debate.
  • Identification of Approaches to Simulated Leachable Studies: What are They? W...
    Identification of Approaches to Simulated Leachable Studies: What are They? W...
    Jason Creasey, Managing Director at Maven E&L and Karen Pieters, Ir. Team Leader E&L at Nelson Labs Europe Recorded: Feb 3 2020 81 mins
    Full Title: Identification of Approaches to Simulated Leachable Studies: What are They? When to do Them?

    Presented by Jason Creasey, Managing Director at Maven E&L Ltd. Followed by an Industry Perspective presentation presented by Karen Pieters, Ir. Team Leader Extractables and Leachables at Nelson Labs Europe

    The term “Simulated leachable studies” is open to interpretation. I hope to provide a definition of this term and in doing so suggest when they can and should be used. The general aim of such studies is to provide an accurate qualitative and quantitative description of the substances which might be present as leachables in a pharmaceutical drug product (DP) derived from container closure system (and sometimes its manufacturing process) when the drug product is stored up to and including its shelf-life. Simulated studies provide an alternative to analysis of leachables directly in the drug product. A simulated study aims to avoid some of the downfalls of leachable analysis such as; inaccurate analysis of leachables due to interference from drug product and/or formulation elements, availability of stored DP samples, reaching required limits of detection in the DP and time / resource constraints associated with complex method development using DP.
    Simulated leachable studies must be able to accurately simulate the expected leachables in a DP and should be carefully crafted to achieve this. The system used for extraction must have similar propensity to leach from materials under study a drug product and care must be taken not to use system which either leach too much (potentially masking other substance) or too little.
  • Identification of unknown extractables and leachables using mass spectrometry...
    Identification of unknown extractables and leachables using mass spectrometry...
    Petra Booij, Investigator at GlaxoSmithKline & Dr Kyle D’Silva, Pharma & BioPharma Marketing Leader, Thermo Fisher Scientific Recorded: Jan 30 2020 58 mins
    Full Title: Identification of unknown extractables and leachables using mass spectrometry: Identification with confidence?

    Extractable and Leachable (E&L) studies on materials used in the manufacturing process and container closer systems of drug products and drug substances are commonly used to assess the risk for patient exposure. Most often LC-MS or GC-MS is used to detect, identify and then quantify extractables and leachables. In general, an analytical evaluation threshold or reporting threshold is set based on a calculated patient exposure. Substances above the set threshold required further investigation if patient exposure exceeds this. Substances can be identified using mass spectral libraries to enable a toxicological risk assessment which considers the risk of patient exposure. However, how confident are we when we identify a substance using spectral libraries? A match with mass spectral libraries, data from orthogonal techniques, fragmentation data and availability of a certified reference standard can increase the level of confirmation. We will discuss an approach for different levels of identification and how to increase the level of confidence of identified extractables and leachables
  • Qualification of Raw Materials and Cell Substrates for Biomanufacturing
    Qualification of Raw Materials and Cell Substrates for Biomanufacturing
    Maura Kibbey Senior Scientific Fellow, Global Biologics at USP and Martin Wisher, Global Head of Regulatory Affairs at Merck Recorded: Jan 16 2020 84 mins
    Presented by Maura C. Kibbey, Ph.D., Senior Scientific Fellow, Global Biologics U.S. Pharmacopeia
    Followed by an Industry Perspective presented by Martin Wisher, PhD, Global Head of Regulatory Affairs at Merck

    The quality of starting materials is critical for successful pharmaceutical manufacturing strategies. For biomanufacturing the challenges are further amplified due to the use of a wide variety of raw materials, cell lines, and naturally-derived materials with an increased risk for the introduction of unwanted impurities and adventitious agents. This presentation will provide an overview and updates on USP documentary standards containing best practices for qualifying incoming materials, demonstrating viral clearance, cryopreservation, cell banking, and controlling impurities derived from cell substrates for therapeutic proteins.
  • The Next Oil Boom: Patents Play Major Role in Next Phase of CBD/THC Legalization
    The Next Oil Boom: Patents Play Major Role in Next Phase of CBD/THC Legalization
    Nextleaf Solutions & PatSnap Recorded: Jan 15 2020 32 mins
    As more governments around the world legalize cannabis, large multinational companies including big tobacco and pharmaceutical companies will try to enforce intellectual property rights in effort to dominate the global market for legal cannabinoid-based products.

    Nextleaf Solutions – a Vancouver-based cannabis extraction company – sees tremendous first-mover advantage in acquiring and developing intellectual property into issued patents in the United States, Canada, and in international jurisdictions where cannabis is federally legal. In 2019, the Company’s IP portfolio ballooned to 10 issued patents and over 45 pending patents around what the Company believes to be the most efficient methods for producing distilled CBD and THC oil.

    Join guest speaker Paul Pedersen, co-founder and CEO of Nextleaf Solutions, for a complimentary webinar on January 15 at 4pm GMT/11am EST to discuss:

    • Why patents are becoming increasingly important in the cannabis and hemp industry
    • The investment opportunity in the next phase of cannabis legalization
    • Why large multi-national companies in more mature industries including big tobacco, alcohol and pharmaceuticals are getting into cannabinoids
    • How turning intellectual property into issued patents, and first-mover advantage, will differentiate those entering the cannabis industry
    • How Nextleaf’s patented proprietary technology will disrupt the space
  • A Cultured Life: Innovations in Spheroid and Organoid Models
    A Cultured Life: Innovations in Spheroid and Organoid Models
    Shuang Zhang, PhD Postdoctoral Fellow NYU School of Medicine, Sonia Iyer, PhD, Jens Eberhardt CEO & Co-founder Automated Lab Recorded: Jan 8 2020 67 mins
    Scientists strive for recapitulation. A seemingly odd goal to reach for at first glance, yet, during experimentation, a fundamental objective is to introduce as few variables as possible while simultaneously trying to recreate in vivo conditions as closely as possible. For decades, two-dimensional cell culture was not only the best way to study the cell biology of healthy and diseased tissue—in many cases, it was the only way. But now, we are in the 21st century, and technological innovations in biomedical sciences have allowed investigators to get closer than ever to an accurate recapitulation of tissue and organ systems. Advanced 3D cell culture methods, such as the development of spheroids and organoids, have become increasingly popular and are revolutionizing approaches to drug discovery, cancer research, and other disease modeling applications. These more in vivo like models show great promise in furthering research in critical areas by delivering more physiologically relevant results.

    In this on-demand GEN webinar, the presenters explore two 3D cell culture paths: one using complex organoid models and CRISPR/Cas9 technology to understand the tumor microenvironment, including gene expression signatures and responses to immunotherapies. The other using novel microcavity spheroid technology to generate thousands of viable and productive monoclonal cell lines for several applications.
  • オルガノイド培養とハイスループット化の試み
    オルガノイド培養とハイスループット化の試み
    コーニングインターナショナル株式会社 ライフサイエンス事業部 江藤哉子 Recorded: Dec 17 2019 63 mins
    スフェロイドとオルガノイドの違いに始まり、オルガノイドの活用や2020年1月発売予定の新製品、マトリゲル基底膜マトリックス オルガノイド形成用を使用した、3D気道オルガノイドのハイスループット遺伝子発現解析についてお話します。

    <セミナーのポイント>
    オルガノイドとスフェロイドとの違いやオルガノイドの特長について、実例や画像を交えながらご紹介します。
  • Learn how Lancet editors decide which papers to accept for publication
    Learn how Lancet editors decide which papers to accept for publication
    Heather Van Epps, Editor-in-Chief The Lancet Rheumatology Recorded: Dec 12 2019 70 mins
    Join Heather Van Epps, Editor-in-Chief of The Lancet Rheumatology, to learn about techniques and strategies for preparing your paper to submit to high-impact journals.

    Heather will share her experiences working with researchers and authors throughout the research publishing cycle. You will learn how to develop papers for submission to publications like the Lancet family of journals.

    Do not miss this engaging webinar―you are invited to join and ask any questions that you feel will benefit your research.

    Don't forget to download your manuscript checklist from the resources section.
  • Clone Wars: An In Depth Look at Mouse vs Rabbit Antibodies
    Clone Wars: An In Depth Look at Mouse vs Rabbit Antibodies
    Faris Omary and Leah Hartman Recorded: Dec 11 2019 40 mins
    Have you ever found yourself wondering which clone of Napsin A to use? What about PAX-8? Or the ongoing dilemma of ordering a mouse monoclonal vs rabbit polyclonal? Then this webinar is for you!
    In this presentation we will explore how antibody's are produced in their corresponding hosts. From there we will identify the main differences between the most popular types of antibodies, including mouse and rabbit monoclonals, and rabbit polyclonals. We will then compare the performance of specific clones that are backed by NordiQC data. We hope this will aid in choosing the best clone for your IHC tests.
  • Internal Collaboration: Using the IR to Build a Promotion and Tenure Package
    Internal Collaboration: Using the IR to Build a Promotion and Tenure Package
    Debra Rodensky and Chip Wolfe, Embry-Riddle Aeronautical University Recorded: Dec 11 2019 39 mins
    At Embry-Riddle Aeronautical University, world-class experts conduct cutting-edge air and space research, and the Library works diligently to capture and share all the unique work through their institutional repository. When the Chief Information Officer asked library staff for help creating a Promotion and Tenure tool to better serve faculty looking to advance, librarians Debra Rodensky and Chip Wolfe knew they had the technology, all the content of the IR and the strong campus relationships to make it happen. Join Debra and Chip on December 11 for a webinar on the Library's collaboration with IT and the library’s relationships with faculty through the tenure and promotion process. Topics will include:
    - The historical relationship between the Library, its IR and the IT department at Embry-Riddle
    - The changing culture of promotion and tenure on campus
    - Challenges and successes of building a tool to meet the needs of both IT and faculty.

    Debra has a BA in Legal Studies from Quinnipiac University and a MLS from the University of South Florida. She has worked as a librarian at the Museum of Science & Industry in Tampa, the Veterinary Library at Disney’s Animal Kingdom, and the Horticulture Library at Walt Disney World before joining the Research Department at ERAU’s Hunt Library in 2001. She now works as a Scholarly Communication Librarian who assists faculty, students, and staff with adding their research works to the institutional repository.

    Chip has been at ERAU’s Hunt Library since 2005 and serves as the Scholarly Commons Administrator. He was instrumental in bringing up and developing the repository that began in 2013. Previous careers include US Naval Security Group, Digital Imaging Service Director, and owner of East Coast Archiving.
  • Relevance of index databases in navigating data and information in Chemistry
    Relevance of index databases in navigating data and information in Chemistry
    Jürgen Swienty-Busch, Elsevier and Ye Li, PhD, MLIS Chemistry and Chemical Engineering Librarian, MIT Recorded: Dec 10 2019 58 mins
    This webinar will examine how index databases can help navigate chemical information efficiently, and how the structured chemical data may enable innovative discoveries. Attendees will be able to:
    •Understand the intellectual value of chemical data and literature indexing
    •Explore functionalities based on indexing and taxonomy in databases
    •Recognize innovative and computational trends of using structured chemical data
  • Ask a Corning Scientist: 3D Cell Culture and Bioprocess
    Ask a Corning Scientist: 3D Cell Culture and Bioprocess
    Audrey Bergeron, Applications Scientist & Ann E. Rossi, Ph.D, Senior Bioprocess Applications Scientist, Corning Life Sciences Recorded: Dec 5 2019 31 mins
    Advanced cell culture techniques and scale-up offer exciting research opportunities; however, they also come with complex challenges and questions. Corning Life Sciences knows cells – you might even say it’s in our DNA with over 100 years of experience in the field.

    In this webinar, Corning scientists put their expertise in the areas of 3D cell culture and bioprocess to work as they answered submitted questions from the audience.

    Webinar highlights:
    •Our lab is new to working with spheroids. What are some options for spheroid formation? (2:02 - 4:10)
    •How do you perform media changes in the 96-well Corning spheroid microplate without losing spheroids? (4:11 - 5:49)
    •How do you dissociate single cells from a spheroid for analysis? (5:50 - 6:51)
    •How do you transfer spheroids? (6:54 - 7:30)
    •What is the surface area of the Corning® CellSTACK® 10-layer vessels? (7:56 - 10:02)
    •Is there an easier way to fill Corning CellSTACK 10-layer vessels? (10:03 - 11:33)
    •What is the maximum culture volume for the 5L expansion bag? (11:34 - 13:25)
    •What cell types can I culture in the 5L Erlenmeyer flask? (13:26 - 15:25)

    Live Q&A session with audience (16:10 - 29:30)
    •How do you prevent organoids from sticking to collection tubes?
    •How do I check the cell confluence in a HYPERFlask?
    •And many more questions
  • Special Joint Webinar on Three-dimensional Models and Retinal Organoids
    Special Joint Webinar on Three-dimensional Models and Retinal Organoids
    Franziska Wienholz and Philip Wagstaff Recorded: Dec 5 2019 50 mins
    Three-dimensional Models: Organoid Study and Co-culture for Oncology
    Three-dimensional (3D) cell culture environments provide structural and biochemical clues for cellular differentiation and functionality. For specialized cell types such as primary cells and stem cells, a two-dimensional (2D) growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, spheroid formation, signal transduction, and tissue-specific gene expression. This seminar will introduce the newest tools developed to help researchers: Corning® Matrigel® matrix for organoid culture and Corning Elplasia® plates for bulk production of spheroids. We will also present advanced case studies using spheroids and organoids.

    Presenter:
    Franziska Wienholz is a Scientific Support Specialist at Corning Life Sciences.

    Retinal Organoids: Developing Disease Models to Better Understand Glaucoma Pathogenesis
    Glaucoma refers to a group of complex genetic diseases that affect the retinal ganglion cells that relay visual input along the optic nerve to the visual cortex. In glaucoma, these cells are damaged and degenerate, resulting in permanent progressive visual field loss and ultimately, blindness. Retinal organoids are routinely used to model glaucoma in vitro; however, a drawback is the lengthy culture times to generate retinal ganglion cells, which can be 2 months or longer. This can be reduced by using a 3D Corning Matrigel matrix culture, which has been used to generate retinal ganglion cells in just 28 days. With advances in gene editing, retinal organoids can be used to model genetic mutations that lead to the development of glaucoma and provide clues to future therapies to halt the loss of vision.

    Presenter:
    Philip Wagstaff is currently a Ph.D. researcher studying the genetics of glaucoma at University of Amsterdam, Netherlands.
  • Leverage PK data in PharmaPendium to inform drug development strategies
    Leverage PK data in PharmaPendium to inform drug development strategies
    Marnix Wieffer Recorded: Dec 5 2019 49 mins
    Pharmacokinetic information from FDA and EMA regulatory documents informs translational and clinical development decisions and may lead to more successful drug development and regulatory approval strategies.

    Pharmacokinetic information from FDA and EMA regulatory documents informs translational and clinical development decisions and may lead to more successful drug development and regulatory approval strategies.
    Join solution marketing manager Dr. Marnix Wieffer for this webinar, where he will discuss how to leverage extracted pharmacokinetic data from literature and FDA/EMA Drug Approval documents to make better-informed decisions on which drugs have the most potential to succeed in clinical development.

    Using PharmaPendium we will
    •Retrieve detailed information on PK parameters on approved drugs
    •Retrieve all data on PK parameter of interest (for example Cmax) on drug acting on the same target I am working on
    •Investigate what is the best translational model to assess Serum protein binding
    •And much more
  • Reaxys training webinar
    Reaxys training webinar
    Dr Marta da Pian Recorded: Dec 5 2019 40 mins
    This webinar will focus on Structure searches in Reaxys.

    - MarvinJS/ChemDraw editor (drawing tools and checkbox panel)
    - Reaction search (product/reagent/catalyst, Atom mapping, Reacting center)
    - Diving into the Result panel
  • From Homegrown to Commercial PIM: Transition Strategies for Success
    From Homegrown to Commercial PIM: Transition Strategies for Success
    Alison Tran, Client Partner, EIS; Chantal Schweizer, Principal Consultant, EIS Recorded: Dec 4 2019 53 mins
    As your business and product data complexity grows, so too may your need for an enhanced PIM system that accounts for numerous operating units, separate companies, global operations, and more.

    How do you judge whether you are ready to jump from your homegrown solution? And if you’re ready to make the jump, what is the best path to ensure that you transition from one system to another successfully?

    In this session you will learn:

    * The milestones that signal your readiness to take on a commercial PIM
    * Best practices when making the transition to a commercial PIM
    * How to align your PIM strategy to a logical data model

    SPEAKERS
    Alison Tran, EIS, Client Partner, brings over 14 years of business and technology consulting experience in technology adoption, software implementation, organizational redesign, change management and process reengineering.
    Chantal Schweizer, EIS, Principal Consultant, a senior information organization professional with over 10 years experience in product information and taxonomy design.
  • The Science of Healthcare Congresses
    The Science of Healthcare Congresses
    Eva Thalmann, Janssen, Jean-Yves Douillard, ESMO, Katie Koziol and Andrew Moore, Ashfield Meetings & Events Recorded: Dec 3 2019 70 mins
    Research from Ashfield Meetings & Events clearly demonstrates that face-to-face meetings and events form a major part of continuing medical education (CME). National and international congresses have been identified as the primary event to attend by HCPs.

    But what makes congresses such a valuable education channel for time-restricted physicians? This pharmaphorum webinar, in association with Ashfield Meetings & Events, will dive into a unique study of HCP educational and behavioural preferences towards attendance at medical congresses.

    Ashfield Meetings & Events’ The Science of Healthcare Congresses study, involved over 200 HCPs, drawn from a range of therapy areas, from both Europe and the US to ask what really matters to them and share some intriguing insights.

    These encompassed how HCPs value this type of activity, how they apportion their time on-site and engage with the healthcare industry, and how they evaluate a congress once its doors have closed for another year.

    Join our expert panel on Tuesday 3rd December to find out more on:

    • Why physicians attend congresses
    • How to ensure medical education provides value to attendees
    • How pharma can enhance industry symposia

    In addition, our panel will also share the results of an ongoing association and multi-pharmaceutical company research project, designed to standardise and benchmark the evaluation process of all congress medical education activities.
  • Effective and Compliant Literature screening for Pharmacovigilance
    Effective and Compliant Literature screening for Pharmacovigilance
    Jean Dominique Pierret Recorded: Dec 3 2019 47 mins
    Biomedical literature is an important source of adverse event reporting. However, due to the high volume of literature, sub-optimal search strategies and regulatory pressure, pharmaceutical companies and CROs are facing significant challenges around costs, efficiencies, oversight and regulations.

    During this webinar, Dr Jean Dominique Pierret, Customer Consultant Pharmacovigilance at Elsevier, will discuss how, through query design, prioritization technology and outsourcing we can significantly improve efficiency and compliance of literature screening.
    We will explore:
    1.The optimization of queries in literature databases
    2.The benefits if literature workflow management
    3.Efficiency gains through prioritization
    4.How outsourcing can support efficiency gains
  • Importance de la surveillance microbiologique de l'environnement de fabrication
    Importance de la surveillance microbiologique de l'environnement de fabrication
    Christian Poinsot, Président Groupe Icare, Sabine Bessières Recasens Field Marketing Manager Environnemental Monitoring Life Recorded: Dec 3 2019 76 mins
    Il s’agit d’un webinar visant la stratégie de maîtrise de la qualité des dispositifs médicaux stériles avec un renforcement de leur réglementation et l’intérêt croissant de la surveillance environnementale de leurs zones à risque de fabrication donc à atmosphère maitrisée
    Rappel des bases de la surveillance de la biocontamination environnementale -Air Surface Personnel - des zones à atmosphère contrôlée des DM et informations sur le nouveau projet de norme européen EN 17141 sur le contrôle de la biocontamination des salles propres en préparation avec une annexe dédiée.
  • How to apply global brand strategies to every customer interaction
    How to apply global brand strategies to every customer interaction
    Massimiliano Siciliano, Grunenthal, Kasper Jerlang, LEO Pharma, Alejandra Betancourt, Anthill Agency, Dom Tyer, pharmaphorum Recorded: Nov 28 2019 62 mins
    Pharmaceutical companies spend a huge amount of time and resources on creating valuable brand strategies, but when they come to life there’s often a disconnect.

    Strategy and execution can easily drift apart when tactics come to life, making it harder for them to drive business and deliver on the long-term action plans to engage with healthcare professionals.

    This is as true for eDetailing or closed-loop marketing initiatives as it is for multichannel marketing strategies that encompass the latest chatbot technology or innovative digital content platforms.

    To remedy this, those working in pharma on multichannel marketing, brand planning and digital need to apply the human factor to their global brand strategies to achieve the kind of tactics that deliver on strategic goals.

    Focus

    Join Anthill on Thursday 28th November from 13:00 GMT / 14:00 CET for a live expert panel discussion on multichannel marketing, brand planning and how to apply global brand strategies in pharma to every customer interaction for greater HCP reach and return-on-investment.

    In addition to looking at brand planning across pharma, common frustrations for the industry and whether or not brand planning is set up to deliver good multichannel marketing, the webinar will also cover:

    • The most common challenges in the brand planning process
    • How to build executional and strategic understanding across an entire brand plan
    • How to activate your existing channels and create the best channel mix for customers
    • How insight-based multichannel marketing can drive strategy and build new insights for the future

    The pharmaceutical industry has been making great progress in its digital transformation, but boundaries are there to be pushed if companies want to continue to innovate their marketing practices and processes.
  • Monitoring Impurities in Biologics
    Monitoring Impurities in Biologics
    Diane McCarthy, PhD, Senior Scientific Liaison, Global Biologics, US Pharmacopeia  Recorded: Nov 26 2019 60 mins
    The complexity of biotherapeutic products and their manufacturing processes can yield a variety of impurities, which must be monitored and controlled to minimize safety concerns and ensure product quality. These impurities can be broadly grouped into two categories: 1) product-related impurities, such as precursors, aggregates and degradation products, and 2) process-related impurities, such as host cell DNA, host cell protein, and particulates.  This presentation will provide an overview of approaches for monitoring impurities, including a discussion of existing USP standards and standards under development to support impurity testing.

    Presented by Diane McCarthy, PhD, Senior Scientific Liaison, Global Biologics, US Pharmacopeia 

    Dr. McCarthy is a Senior Manager, Science and Standards within USP’s Global Biologics Department. Diane works with stakeholders to identify areas where standards are needed and define and develop new standards. Prior to joining USP, Dr. McCarthy was Senior Scientific Director at Caprion Biosciences, where she focused on the use of mass spectrometry for characterization of biologics and host cell proteins. Her previous roles also included Director of Scientific Affairs at Ezose Sciences, where she focused on identification and quantitation of glycans by mass spectrometry and Global Manager, Biomarker Research Center, at Bio-Rad Laboratories, where she directed translational and biomarker research contracts and collaborations with industry, key consortia, academic, and government groups.
  • Learn valuable tips for impactful submissions from a Lancet editor!
    Learn valuable tips for impactful submissions from a Lancet editor!
    John McConnell, Editor-in-Chief of The Lancet Infectious Diseases Feb 20 2020 10:00 am UTC 76 mins
    Hear John McConnell, Editor-in-Chief of The Lancet Infectious Diseases, discuss how to prepare a manuscript for submission to leading journals and answer author's most frequently asked questions about the submission process. Due to the high level of engagement and positive feedback received from research communities around the globe, we are now making the recording of this webinar available to you.

    You can expect to learn:
    • How to choose a journal for submission
    • What to include in each section of your manuscript
    • The editorial decision-making process
  • How Adobe Sign plays a role in your workplace
    How Adobe Sign plays a role in your workplace
    Steve Walker, Solutions Consultant, Adobe Feb 25 2020 10:00 am UTC 39 mins
    Join us in our virtual, animated studio for this video webinar to learn how countless businesses around the world use Adobe Sign to accelerate their business processes and eliminate the paper trail and waste previously involved.

    Register for this webinar to discover:
    • The immediate value of implementing electronic signatures with Adobe Sign
    • How easy it is to add signature fields to documents and send
    • How to embed a form for signature directly within your company’s website
    • How to save time by creating powerful workflows for regularly used processes
    • How you can deploy simply and easily for immediate results.

    There will be live Q&A session at the end of the webinar.
  • Innovation at Cell Press: How can librarians make the most of resources
    Innovation at Cell Press: How can librarians make the most of resources
    Dr. Deborah Sweet, Senior Vice President of Publishing, Cell Press Feb 25 2020 4:00 pm UTC 60 mins
    Learn all about innovation, growth in the multi-disciplinary content and the expanding open access publishing strategy at Cell Press with Dr. Deborah Sweet, Senior Vice President of Publishing at Cell Press. You can expect to learn more about the community outreach programs at Cell Press like webinars, symposia, Cell Mentor, Sneak Peek, STAR Methods, STAR Protocols and much more which can help your researchers as well as institutes to grow faster and deliver a higher impact in the world. We promise to make the webinar engaging and to answer all your questions around Cell Press. At Cell Press, everything we do aims to drive research forward — whether it's working with authors, enhancing the peer review process, or developing innovations in publishing. We put science first, science that people talk about. Join Dr. Sweet in this engaging webinar and make sure to bring along your colleague and friends who may benefit from these helpful resources.
  • Mobile molecules: Keeping on track
    Mobile molecules: Keeping on track
    Prof Hagan Bayley and Dr Yujia Qing, University of Oxford Feb 26 2020 2:00 pm UTC 60 mins
    Join the University of Oxford’s Professor Hagan Bayley and Reaxys PhD Prize 2019 winner Dr. Yujia Qing on February 26 for an exclusive look at their contributions to chemical nanotechnology. Professor Bayley will open the webinar by sharing his success in transforming a pore-forming protein into a stochastic sensor and a protein nanoreactor. Then Dr. Qing will discuss her work with a remarkable nanomachine: the molecular hopper that can move directionally along a protein track. Attendees can ask questions during a live Q&A at the end of the webinar.
  • Predicting drug-drug interactions to reduce adverse event risk
    Predicting drug-drug interactions to reduce adverse event risk
    Marnix Wieffer Feb 26 2020 3:00 pm UTC 45 mins
    Adverse drug reactions (ADRs) are a serious problem worldwide. One reason for the increase in ADRs is the growth in prescription use—especially among aging populations where drug–drug interactions (DDIs) are more likely. Currently, 9 percent of Americans over age 55 take 10 or more prescription drugs, which greatly increases the likelihood of DDIs and ADRs.

    Identifying potential drug-drug interaction risk is a key priority for pharmaceutical manufacturers and regulatory authorities. To minimize health risks to clinical trial subjects and patients, assessments should be performed as early as possible in development.
    Join solution marketing manager Dr Marnix Wieffer for this webinar where he will discuss outstanding issues with predicting Drug-drug interaction risk and possible solutions. We run through a couple of live examples that show how PharmaPendium is supporting Drug-drug interaction risk prediction.
    Using PharmaPendium we will investigate
    •What enzymes and transporters act on my drug of interest?
    •What is the DDI risk for drugs that are substrates CYP2D6?
    •What is the DDI risk of my drug under development with Antiarrhythmic drugs?
  • 20 Cool Things to do with Digital Commons
    20 Cool Things to do with Digital Commons
    Christine Yang, Digital Commons Consultant Feb 26 2020 4:00 pm UTC 45 mins
    As the world of digital scholarship has expanded, the role of the IR has evolved along with it. Whether you’ve been using Digital Commons for Digital Commons for 6 months or 6 years, the modern repository showcases more than just faculty articles. Join Digital Commons Consultant Christine Yang as she explores some of the exciting developments we are seeing on Digital Commons repositories. Attendees will come away with ideas for their next project, including:
    - New types of content, like podcasts, oral histories, and bilingual and foreign language journals
    - Interactive features, like native streaming and timelines
    - Technical capabilities built into the system, including accessible cover pages and Plum X Metrics
  • Drug repurposing for rare diseases: an integrated data driven approach
    Drug repurposing for rare diseases: an integrated data driven approach
    Jabe Wilson; Megan Golden Feb 27 2020 3:00 pm UTC 60 mins
    Pharma R&D for rare diseases is, itself, rare, because patient populations are perceived as insufficient to deliver ROI. Drug repurposing eliminates the expensive process of discovering a completely new compound, shortens the time that is needed to reach the patients, and ensures a higher success rate.

    Elsevier and Pistoia Alliance organized a drug-repurposing datathon, with Cures Within Reach and Mission: Cure being the consulting organizations. The objective was to identify repurposable drug candidates for chronic pancreatitis – a rare disease that affects about 1 million people globally, and currently doesn’t have an approved treatment. As a result, this datathon identified 4 drug candidates in 30-60 days. They were reviewed and approved by the expert panel, pending further clinical trials by Mission:Cure.

    This webinar will talk about this unique non-profit and private collaborative datathon, using Entellect, an AI-powered technology platform for identifying repurposable drug candidates for chronic pancreatitis.

    The topics will include:
    - Introduction to datathon
    - Predictive analytics for drug repurposing - needs and challenges
    - Established strategy and workflow
    - Outcome and impact
    - Update to the clinical trial progress

    About speaker:
    Jabe Wilson, Global Commercial Director, Data and Analytics, Elsevier
    Megan Golden, co-founder and co-director, Mission: Cure
  • How Adobe Document Cloud can help you achieve a paperless office
    How Adobe Document Cloud can help you achieve a paperless office
    Steve Walker, Solutions Consultant, Adobe Mar 3 2020 10:00 am UTC 24 mins
    Join us in our virtual, animated studio for this video webinar to discover how Adobe Document Cloud can help you unlock the power of digital document workflows. You’ll learn how to do the following:

    • Obtain accountability and tracking capabilities for every document
    • Give your teams the power to deliver paperless experiences to customers on any device
    • Create forms in Adobe Acrobat and Microsoft Office
    • Automate the storage of documents in Microsoft SharePoint
    • Build intelligent document workflows using Adobe Sign and Microsoft Flow
    • Ensure better security, collaboration, and organisation within your company.

    There will be live Q&A session at the end of the webinar.
  • Sampling Devices for In-line near Infrared Spectroscopy Monitoring of Powder Ble
    Sampling Devices for In-line near Infrared Spectroscopy Monitoring of Powder Ble
    Anders Sparén Associate Principal Scientist at AstraZeneca and Ed Gooding, MicroNIR Photonic Applications Specialist at VIAVI Mar 3 2020 2:00 pm UTC 90 mins
    Sampling Devices for In-line near Infrared Spectroscopy Monitoring of Powder Blend Homogeneity in Continuous Manufacturing

    In continuous direct compression of pharmaceutical formulations, it is essential to assess the homogeneity of powder blends. This could preferably be done in situ, using fast spectroscopic techniques. In this study, near-infrared spectroscopy was used to study powder blend homogeneity at two positions in the continuous manufacturing process; after the first blender and in the tablet press feed-frame. The focus of the study was on sample presentation at the two positions, and several sampling devices were tested in a laboratory setting using a model formulation, aiming at improving the quality of the NIR measurements. The results for the sampling devices tested are compared and the future implementation in the continuous manufacturing equipment is discussed.


    Followed by Powder Blend Homogeneity Monitoring with the Viavi MicroNIR PAT-W

    The MicroNIR PAT-W wireless NIR spectrometer is used in monitoring blend uniformity in pharmaceutical manufacturing. The PAT-W is a rugged, IP65/67 rated instrument with no moving parts. The PAT-W, with >8 hours battery life, WiFi communication and onboard gravity sensor is well suited for use on tumble blenders in regulated facilities. Viavi’s Linear Variable Filter technology, optical fiber-free design and dual onboard tungsten lamps ensure excellent stability, long lifetime and minimal instrument-to-instrument variability. Viavi MicroNIR Pro software provides data acquisition and chemometric model building, and assures compliance with Title 21 CFR Part 11, USP chapter 1119 and EP chapter 2.2.40. OPC communication and control are also available for use in process environments.
  • Real-time Sequencing by FTIR in GMP Oligonucleotide Synthesis
    Real-time Sequencing by FTIR in GMP Oligonucleotide Synthesis
    John-David McElderry, Scientist at Biogen and Dominique Hebrault, Science & Technology Business Development at Mettler-Toledo Mar 4 2020 3:00 pm UTC 90 mins
    Presented by John-David McElderry, Scientist at Biogen
    Followed by an Industry Perspective presented by Dominique Hebrault, Science & Technology Business Development at Mettler-Toledo International, Inc

    John-David McElderry graduated from University of Michigan with his PhD in 2012 and has been an analytical scientist and PAT expert in the Pharma/Biotech industry for seven years. He started his career at Vertex Pharmaceuticals creating PAT applications for the first continuous DP manufacturing rig and helped develop the first real-time release strategy in the industry. He is currently at Biogen where he has developed PAT-based control strategies for continuous flow chemistry of small-molecule drugs and continuous synthesis of oligonucleotide drugs. He is interested in enabling real-time control of quality attributes in pharmaceutical manufacturing through the application of smart sensors and machine learning.
  • Harnessing the Power of Data Analytics to Derive Process Intelligence for Pharma
    Harnessing the Power of Data Analytics to Derive Process Intelligence for Pharma
    Santosh Whatkar, Senior Manager, Automation and Digital Technology at Pfizer Mar 5 2020 8:00 am UTC 90 mins
    Full Title: Harnessing the Power of Data Analytics to Derive Process Intelligence for Pharma Manufacturing

    Presented by Santosh Whatkar, Senior Manager, Automation and Digital Technology at Pfizer

    At Pfizer Singapore, significance of Data Analytics was realized after a period of 1 and half years when we were able to successfully implement the pilot use cases enabling us with Digital capabilities.

    It would be a sharing with the audience about the Pfizer, Singapore journey of Digital Transformation and the various learnings along the way; which enabled several attributes from teamwork, persistence, believing the vision and doing things differently.  Data Analytics significance was realized after passing through this journey and we were enlightened with the amazing capabilities existing data can have. Although our problem statements existed for several years, the change in perspective of using Digital technologies and existing data enabled us to find robust solutions.

    Below case studies would elaborate more on the enhancing Pfizer’s manufacturing robustness  leveraging on Digital Transformation capabilities –

    Case Studies:

    • Model based real time estimation of loss of drying
    • Model based predictive ability of failure for automated valves
    • Virtual sensors for energy monitoring in manufacturing environment

    Case Study:  

    • Process condition monitoring using Machine Learning
  • Must Know Tips for Publishing in Premium Journals
    Must Know Tips for Publishing in Premium Journals
    Dr. Philip Earis, Editor-in-Chief, Joule, Cell Press Mar 5 2020 9:00 am UTC 60 mins
    Join Dr. Philip Earis, Editor-in-Chief of Joule (Cell Press journal) for an engaging webinar to learn about techniques and strategies for authoring in high impact journals. Dr. Earis will present his experience working with researchers and authors throughout the research publishing cycle, how to develop papers for premium publications, and the opportunity to broadly disseminate findings. Dr. Earis will talk to you about growth of Cell Press journals in the physical sciences field, which includes launch of many new titles such as Chem, Joule, Matter, and One Earth. He’ll also outline Cell Press’ approach to high-demand, multi-disciplinary content, and expanding OA publishing strategies at Cell Press. You won’t want to miss this informative webinar and how it can benefit your research process and impact. Please extend this invite to colleagues who may also find it of interest.

    More about Dr. Philip Earis:
    Philip is a graduate of Cambridge University in England and brings over 10 years of experience in publishing impactful energy research to Joule. He came to Cell Press after 3 years of living in India, where he founded and ran Project Light, an organization bringing solar power to marginalized off-grid communities in India. In this role, he worked closely with Indian and international scientists to develop and install appropriate solar energy technology.
  • In Situ High Speed NIR Imaging to Monitor Form Change and Drug Release from...
    In Situ High Speed NIR Imaging to Monitor Form Change and Drug Release from...
    Patrick Wray, Senior Research Investigator, BMS and Miriam Böhmler, Senior Applications Scientist at WITec GmbH Mar 10 2020 10:00 am UTC 90 mins
    Full Title: In Situ High Speed NIR Imaging to Monitor Form Change and Drug Release from Rapidly Disintegrating Tablets
    Presented by Patrick Wray, Senior Research Investigator at Bristol-Myers Squibb

    Spectroscopic imaging is a powerful chemically specific and spatially resolved approach which can be used to effectively monitor tablet dissolution. This work employs Raman mapping and Near Infrared (NIR) chemical imaging to examine drug release from model tablet formulations as complementary technologies. Modern pushbroom type NIR imaging systems allow extremely fast acquisition of chemical images. Consequently this allows us to study the chemical and physical changes which occur during drug release from rapidly disintegrating formulations.
    A custom designed flow through cell is used to carry out the tablet dissolutions in such a way that the sample is presented to the optics of the chemical imaging system being used. The cell is compatible for use with NIR, Raman and Mid IR spectrometers.
    Two types or formulations will be presented: Rapidly disintegrating formulations with varying amounts of super disintegrant and tablets containing a model drug exhibiting fast onset of disproportionation in pH neutral conditions.

    Followed by Cutting-edge Raman Imaging for New Advances in Pharmaceutics
    Presented by Dr. Miriam Böhmler, Senior Applications Scientist at WITec GmbH

    Confocal Raman imaging microscopy is a non-destructive chemical characterization method based on an energy shift in excitation light scattered by molecules or crystal lattices. This is known as the Raman effect and it can be detected by a spectrometer as a Raman peak within a Raman spectrum, which can serve as a “fingerprint” for individual materials in the sample.
  • Antisense Oligonucleotide Purification Process: Successes and Challenges During
    Antisense Oligonucleotide Purification Process: Successes and Challenges During
    Robert Gronke, Ph.D., Senior Principal Scientist, Biogen and Thomas Müller-Späth, Ph.D, CTO at YMC ChromaCon Mar 10 2020 2:00 pm UTC 90 mins
    Full Title: Antisense Oligonucleotide Purification Process: Successes and Challenges During Scale-up

    Presented by Robert Gronke, Ph.D., Senior Principal Scientist, Technical Development, Biogen

    Recently, our first full scale GMP batch for an antisense oligonucleotide was manufactured in the newly built synthesis suite at Biogen. A four-step purification process was then carried out in the existing flexible volume manufacturing facility that, up until this point, has been used for manufacturing Biogen’s protein-based parenterals. This was our first test case to demonstrate that Biogen can manufacture ASOs safely, at scale, and achieve high purity and yield. Results are presented on the scalability of the ASO process from bench to GMP scale, highlighting successes and challenges faced with scale-up of the downstream ASO process.

    Followed by an industry perspective presented by Thomas Müller-Späth, Ph.D, CTO at YMC ChromaCon
  • Applications of Biomedical Knowledge Graph for AI and Machine Learning
    Applications of Biomedical Knowledge Graph for AI and Machine Learning
    Anton Yuryev Mar 11 2020 3:00 pm UTC 60 mins
    Biomedical knowledge graphs (BMKGs) link biomedical entities (such as diseases, proteins, and drugs) through certain defined relationships. They are important tools to computationally analyze the comprehensive body of biomedical knowledge.

    In this webinar, Anton Yuryev, Biology Director at Elsevier will talk about the approaches and use of knowledge graph together with artificial Intelligence algorithms for various biomedical applications such as drug repurposing, personalized drug therapy, and personalized immunotherapy.

    The talk will cover
    - comparing different graph embedding techniques
    - introducing a new graph embedding technique that uses patient OMICs data to calculate node activity using sub-network enrichment analysis
    - how to use node activity to find likely disease mechanism in a patient and use this mechanism to predict personalized treatment or neoantigen vaccine design, or new target discovery

    About speaker:
    Dr. Anton Yuryev has PhD in Genetics from Johns Hopkins University where he discovered proteins physically linking gene transcription with mRNA processing in eukaryotic cells. He worked over 30 years in bioinformatics as Senior Scientist at InforMax, as Senior Bioinformatics Analyst at Orchid Cellmark, and as Senior Director of Application Science at Ariadne Genomics. Dr. Yuryev published over 50 scientific articles, edited four scientific books, authored algorithms for primer design and pathway analysis. He currently serves as Professional Services Director at Elsevier and responsible for development of targeted bioinformatics solutions using Elsevier proprietary software, knowledgebases and artificial intelligence in the areas of drug development, personalized precision medicine, agro- and synthetic biology.
  • The Journey Of Implementing Advanced Process Control In the Pharmaceutical...
    The Journey Of Implementing Advanced Process Control In the Pharmaceutical...
    Olav Lyngberg, Sr Scientific Fellow at Janssen Pharma and Mark Demesmaeker Head of Data Analytics at Sartorius Stedim Biotech Mar 16 2020 2:00 pm UTC 90 mins
    Full Title: The Journey Of Implementing Advanced Process Control In the Pharmaceutical Industry
    Presented by Olav Lyngberg, PhD, Sr. Scientific Fellow, Advanced Technology, Technical Operations at Janssen Pharmaceuticals and

    The presentation will share the journey that Janssen is taking as it progresses its strategy on Advanced Process Control (APC). Within Janssen we aspire to improve our Manufacturing Technology Organization’s performance on key metrics such as cost of goods, on time and in full product delivery, production cycle time, and right first-time process performance. Improving these metrics require a comprehensive technology strategy that can address not just one but all the key metrics together. The strategy that Janssen is pursuing has three pillars. 1: process intensification, 2: modular and flexible designs, and 3: process digitalization and advanced process control. Each pillar contributes differently to the key metrics and in aggregate and when achieved together they make it possible to reach all the goals.

    Followed by Obtaining Increased Observability & Control of the Bioprocess
    Presented by Mark Demesmaeker, Head of Data Analytics at Sartorius Stedim Biotech

    As the biopharmaceutical industry is undergoing the digital transformation, a number of disruptive technology evolutions and market shifts are happening in parallel: Novel approaches in bioprocessing (e.g., intensified and continuous processing) are pushing cells and expression systems to their limits. New process analytical technologies are introduced, including online spectroscopy, advanced single-use sensors, and advanced modeling and simulations. Adding to that a trend towards increased miniaturization and throughput of cell culture processes puts an enormous burden on data streaming, management, and preparation. Recent progress in cellular and gene therapies also contributes to the evolution of bioprocessing.
  • How ‘thinking modular’ might ease digital content overload in pharma
    How ‘thinking modular’ might ease digital content overload in pharma
    Morten Kruse Sørensen, Novo Nordisk, Florent Edouard, Grünenthal Group, Huw Jenkins, Veeva, Kasper Jerlang, LEO Pharma Mar 17 2020 1:00 pm UTC 75 mins
    Overview
    In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based on their target product profile alone.

    Instead, the key factor now is often the quality of customer engagement, which more and more healthcare professionals (HCPs) appear to value.

    It’s enabled by a multichannel marketing (MCM) approach, but traditional MCM strategies require a much higher level of content than pharma is used to producing and approving – the answer to this is a modular approach.

    Such modular content allows pharma to meet HCPs’ information demands by leveraging content assets across multiple channels and in many different combinations, at the same time providing superior targeting and tracking.

    This pharmaphorum webinar, held in association with Anthill, will take place on Tuesday 17 March from 13:00 to 14:00 (GMT)/14:00 to 15:00 (CET) and will look at how the use of modular content in pharma can ease some digital worries.

    Focus
    Our expert panel will discuss:

    •The most common challenges in the digital content creation process
    •Aligning content creation tactics with the multichannel marketing strategy
    •How to activate your existing content to maximise existing resource for the greatest HCP reach
    •Making the customer experience a key differentiator

    Our Panel
    •Morten Kruse Sørensen, Global Director Multichannel Excellence and Operations, Novo Nordisk
    •Florent Edouard, SVP, Global Head of Commercial Excellence, Grünenthal Group
    •Huw Jenkins, Director, DAM Strategy, Veeva
    •Kasper Jerlang, Head of Global Digital Marketing and Engagement, LEO Pharma
    •Tor Kristensen, CTO, Anthill Agency
    •Dominic Tyer, Creative and Editorial Director, pharmaphorum [moderator]
  • Reaxys training webinar - Medicinal Chemistry
    Reaxys training webinar - Medicinal Chemistry
    Dr Marta da Pian Mar 17 2020 2:00 pm UTC 45 mins
    This Reaxys training webinar will focus on Medicinal Chemistry.

    The following topics will be addressed in this session:

    1. Query builder (Target search)
    2. Diving into the Result panel
    3. Heatmap (Structure Activity Relationship)
  • IIoT and AI for Digitalizing Pharmaceutical Manufacturing Operations: From....
    IIoT and AI for Digitalizing Pharmaceutical Manufacturing Operations: From....
    Jun Huang, Director/Team Leader, Automation&Control at Pfizer and Amos Dor, Pharma General Manager & CTO at Applied Materials Mar 17 2020 2:00 pm UTC 90 mins
    Full Title: IIoT and AI for Digitalizing Pharmaceutical Manufacturing Operations: From Hype to Reality
    Presented by Jun Huang, Director/Team Leader, Process Monitoring, Automation & Control at Pfizer

    Driven by increased connectivity enabled by Industrial Internet of Things (IIoT) and more sophisticated data gathering and analytics/AI capabilities, manufacturing is ushering in a new era of production, where information technology (IT) and operation technology (OT) are converging to form so-called cyber-physical systems. IIoT and analytics are key complementary driving forces behind digitalization, enabling a securely connected plant and a streamlined flow of data and information between physical production and digital worlds, as well as prescription of data-driven actions pervasively across manufacturing and quality operations. Use case examples will be given to demonstrate how IIoT and analytics are implemented in practice to drive continual improvement in manufacturing visibility, quality and productivity.

    Followed by an Industry Perspective Presented by Amos Dor, Pharma General Manager & CTO at Applied Materials Automation Product Group
  • Essential tips for publishing in high-impact journals
    Essential tips for publishing in high-impact journals
    Dr. Rose Zhu, Associate Scientific Editor, Joule Mar 18 2020 1:00 pm UTC 75 mins
    Discover the best techniques and strategies for authoring in high impact journals with Dr. Rose Zhu, Associate Scientific Editor at Joule (Cell Press journal). You can expect to learn:
    •Techniques and strategies for improving the scientific writing process including tips on writing a better introduction, creating an effective abstract and analysing the results in your research paper
    •Tactics on developing papers for premium publications
    •Exploring the opportunities to broadly disseminate findings
    •Discover the Cell Press physical science portfolio of journals including newly launched titles such as Chem, Joule, Matter & One Earth

    Dr. Zhu will also outline Cell Press’ approach to high-demand, multi-disciplinary content, and expanding OA publishing strategies at Cell Press.

    Sign up for this interesting free webinar and learn best tips & tricks to benefit your research process and increase your research impact.

    Bring along a friend or colleague who might be instrumental in improving your research paper.

    Here’s a quick introduction about Dr. Rose Zhu:
    Dr. Rose Zhu joined Joule as Associate Scientific Editor in 2017 and is based in the Shanghai office. Since 2017, Dr. Zhu has given over 100 talks on scientific writing and publishing techniques with Joule and other Cell Press physical science journals. Dr. Zhu completed her Ph.D. from Nanyang Technological University (NTU, Singapore) after completing the BSc degree at Sichuan University (China). Dr. Zhu has published 10+ papers in the physical sciences field covering wide array of topics like Nano energy, material horizon and much more.
  • Extractable Data Mining: Common Extractables From Polymeric Manufacturing Materi
    Extractable Data Mining: Common Extractables From Polymeric Manufacturing Materi
    Ping Wang, Director at Johnson & Johnson and Donald DeCou, E&L Technology Manager at West Pharmaceutical Services Mar 23 2020 2:00 pm UTC 75 mins
    Full Title: Extractable Data Mining: Common Extractables From Polymeric Manufacturing Materials Used in Biologics Production
    Presented by Ping Wang, Director at Johnson & Johnson

    • Safety assessment of extractables and leachables is often based on assumption that E&L are highly toxic
    • Most common extractables from about 40 sets of study data indicates that none of them is part of “cohort of concern” per ICH M7 guideline.
    • Safety profiles of common extractables from common single use systems can be used to design a risk-based approach for future materials.

    Followed by Current Trends in Extractables and Leachables Testing from Manufacturing Equipment to Single Use Manufacturing Components
    Presented by Donald F. DeCou, Ph.D, Extractables and Leachables Technology Manager at West Pharmaceutical Services

    There are many types of components that a drug formulation may contact during a typical manufacturing process.  This can range from large volume mixing vessels to filters, tubing and other smaller components.  More recently the use of Single Use Systems (SUS) have been steadily increasing during the manufacture, handling and storage of biologics.  Each contact component has the potential to introduce leachable compounds to the drug formulation.  The BioPhorum Operations Group (BPOG) has developed standardized extractables testing protocol for SUS.  This talk will review some of the central concepts of the BPOG protocol as well as current trends in performing extractable, leachable and simulation studies on manufacturing components and single use systems.
  • Control Strategy and a Real Time Release Testing From a Development Line to...
    Control Strategy and a Real Time Release Testing From a Development Line to...
    Tom Van Den Kerkhof Scientist at Johnson & Johnson and Uwe Kirschner, Managing Director at Sentronic GmbH Mar 25 2020 9:00 am UTC 90 mins
    Full title: Control Strategy and a Real Time Release Testing From a Development Line to Commercial Manufacturing

    Presented by Tom Van Den Kerkhof Scientist at Johnson & Johnson
    Followed by Uwe Kirschner, Managing Director at Sentronic GmbH

    Johnson & Johnson has invested in three different continuous manufacturing lines, where PAT applications are applied to determine the uniformity of the final blend and the core tablets. Two CM lines have been implemented to accomplish the high-volume demand of two commercial products, while a third CM multi-purpose line, allowing to perform wet-granulation, roller compaction or direct compression, has been implemented in the R&D facility for the development of new drug products. In this presentation, the PAT control strategy currently applied for the commercial products as well as the one applied for new products is presented. Furthermore, the use of the generated PAT data to release the final batch is presented for a direct compression commercial product. For this commercial product, the PAT analysis performed on the core tablets by NIR spectroscopy are used to replace the final product testing in the laboratory for the release testing of assay, content uniformity and dissolution.
  • Expert Advice: How to publish in ACC Journals
    Expert Advice: How to publish in ACC Journals
    Valentin Fuster, M.D., Ph.D. Mar 26 2020 9:00 am UTC 75 mins
    Hear Valentin Fuster, MD, Ph.D., Editor-in-Chief of the Journal of the American College of Cardiology (JACC) to learn about techniques and strategies for publishing in high-impact journals. Dr. Fuster presents information on publishing in ACC Journals, which include JACC, JACC: Cardiovascular Imaging, JACC: Cardiovascular Interventions, JACC: Heart Failure, JACC: Clinical Electrophysiology and JACC: Basic to Translational Science. Dr. Fuster presents his expertise in working with researchers and authors throughout the research publishing cycle, how to develop papers for premium publications, and the opportunity to broadly disseminate findings. Due to the high engagement, we received in the original webinar we're making the recording of the webinar available to you on popular demand. You won’t want to miss this engaging webinar and how it can benefit your research process and impact.
  • Tips and Tricks for LC/MS
    Tips and Tricks for LC/MS
    Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA Darmstadt, Germany Apr 2 2020 6:00 am UTC 75 mins
    LC/MS is an excellent tool for analyzing samples. This presentation provides valuable tips and tricks to get the best performance out of your LC/MS instrument regarding sensitivity and limit the instrument downtime by different approaches. In detail HPLC column technologies as well as advanced LC/MS solvents and additives for improved LC/MS performance will be discussed. Furthermore, the use of reference materials as internal standards and for calibration will be addressed. Finally the importance of Sample Preparation for robust and consistent results will be highlighted.
  • Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell
    Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell
    Dan Hill, Manufacturing Scientist at Biogen Apr 2 2020 2:00 pm UTC 90 mins
    Full Title:Advanced Raman Spectroscopy Beyond In-Process Glucose Control of Commercial Cell Culture Processes

    Presented by Dan Hill, Manufacturing Scientist at Biogen

    The use of in-line Raman spectroscopy as an in-line process analytical technology (PAT), in the biotechnology industry, has matured over the past decade from a technology with promise to a standard tool for real-time, continuous monitoring of cell culture processes. There is an ever-growing body of work demonstrating successful application from metabolite and product quality monitoring to process control in both process development and GMP manufacturing environments. This is due, in part, to advances in technology robustness, user- and integration-interfaces, improved sensitivity, and fluorescence rejection. Organizations are now faced with the difficult task of best leveraging these tools and extracting the most value from them. Thus, defining and executing Raman program strategy is critical to the technology’s long-term success and sustainability.

    This presentation will describe Biogen’s past efforts and strategic direction as it relates to in-line Raman spectroscopy for cell culture operations and how we intend to leverage its capability beyond metabolite monitoring and glucose feedback control to become an essential element of our Advanced Process Control efforts.